{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-314746","form_type":"8-K","ticker":"WVE","cik":"0001631574","company_name":"Wave Life Sciences Ltd.","filed_at":"2025-12-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.989616+00:00","generated_at":"2026-05-16T13:30:26.670340+00:00","sec_items":["1.01","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Wave Life Sciences prices upsized $402.5M public offering; extends cash runway to Q3 2028","bullets":["Offering: 15,789,475 shares at $19.00 plus 2,631,578 pre-funded warrants at $18.9999.","Underwriters fully exercised option for additional 2,763,157 shares; total gross proceeds ~$402.5M.","Closing expected Dec 11, 2025; pro forma shares outstanding ~187.7M.","Cash runway extended into Q3 2028; excludes potential milestone payments from GSK collaboration.","Jefferies, Leerink Partners, BofA Securities act as joint book-running managers."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-314746","json":"https://secwatch.observer/filing/0001193125-25-314746.json","markdown":"https://secwatch.observer/filing/0001193125-25-314746.md","text":"https://secwatch.observer/filing/0001193125-25-314746.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1631574/000119312525314746/0001193125-25-314746-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1631574/000119312525314746/d88507d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:30:26.670340+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}